2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Non-Biological Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bleeding and Clotting, Platelet Disorders, Genetic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3836 Integrating clinical and molecular features for predicting clinical outcomes in patients with lower-risk myelodysplastic neoplasms

Zefei Bao, Bing Li, MD2, Tiejun Qin3, Zefeng Xu, MD4, Shiqiang Qu5, Lijuan Pan6, Qingyan Gao7, Meng Jiao8, Gang Huang, MD9, Zhijian Xiao10
1 State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
9 UT Health San Antonio, Joe R. and Teresa Lozano Long School of Medicine, San Antonio, United States
10 State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China

Introduction: The currently available therapeutic approaches for myelodysplastic neoplasms (MDS) vary from watchful observation or supportive care to chemotherapy and early hematopoietic stem cell transplantation. Management of lower-risk MDS (LR-MDS) is generally conservative, with primary goals of alleviating anemia, reducing symptom burden, and improving quality of life. However, LR-MDS exhibits marked heterogeneity in disease course, ranging from indolent disease to progression toward acute myeloid leukemia or bone marrow failure. Therefore, further risk stratification and accurate prediction of distinct clinical outcomes are crucial to better characterize the natural history of LR-MDS and identify patients who may benefit from early intervention or participation in clinical trials.

Methods: A single-center retrospective cohort comprising 730 consecutive patients with newly diagnosed LR-MDS without excess blasts (IPSS-R score ≤3.5 and/or IPSS-M score ≤0) was enrolled. We systematically analyzed the clinical and molecular features and outcomes of patients with LR-MDS and established separate risk prediction models for three different endpoints: overall survival (OS), disease progression (PD) and transfusion dependency (TD).

Results: Multivariate Cox regression analysis with backward stepwise selection identified age at diagnosis, bone marrow blasts, MCV level, ferritin level, and mutations in U2AF1S34, U2AF1Q157, RUNX1, and TP53 as independent predictors of OS. Based on this, a scoring system was developed which stratified LR-MDS patients into six risk categories. Median OS progressively decreased across the risk groups, from not reached in the Very-Low and Low risk groups to 82, 49, 31, and 17 months in the Moderate-Low, Moderate-High, High and Very-High risk groups, respectively (P<0.001). The model demonstrated superior discriminatory ability compared with IPSS-M and IPSS-R, with C-indices of 0.733, 0.609, and 0.531, respectively.

Among 513 patients with complete longitudinal disease course information, multivariate Fine–Gray regression with backward selection identified six independent predictors of PD: bone marrow blasts and mutations in U2AF1S34, U2AF1Q157, RUNX1, ZRSR2, and EZH2. Patients were classified into three risk groups, with 3-year cumulative incidences of PD of 8.4%, 18.2%, and 48.2% in the Low-, Intermediate-, and High-risk groups, respectively (P<0.001). The PD model achieved a C-index of 0.721, outperforming both IPSS-M (0.603) and IPSS-R (0.528).

A TD prediction model was subsequently developed in 428 patients who were transfusion-independent at diagnosis, incorporating baseline hemoglobin level, and mutations in SF3B1, U2AF1S34, U2AF1Q157, EZH2, and ETV6. The cumulative incidence of TD at 3 years increased progressively across the three risk groups, reaching 10.4%, 44.6%, and 81.5% in the Low-, Intermediate-, and High-risk groups, respectively (P<0.001). The TD model showed a C-index of 0.719, superior to IPSS-M (0.618) and IPSS-R (0.539).

Serial next-generation sequencing demonstrated the acquisition of new genetic alterations at the time of PD or TD in 36/47 (76.6%) and 21/56 (37.5%) patients, respectively. Notably, the emergence of novel genetic alterations concurrent with PD or TD predicted inferior survival outcomes. Patients who acquired new genetic alterations at PD had significantly shorter post-progression survival than those without newly acquired alterations (16 months vs. not reached, P=0.019). Similarly, median post-TD survival was significantly shorter among patients with newly acquired genetic alterations at TD compared with those without (29 months vs. 76 months, P<0.001).

Conclusion: The integration of baseline clinical parameters and molecular features enables early recognition of LR-MDS patients at higher risk of adverse clinical outcomes, and may facilitate individualized therapeutic decision-making.

Zefei Bao: No relevant conflicts of interest to declare.